Id Boufker, Hichame
The Src inhibitor dasatinib accelerates the differentiation of human bone marrow-derived mesenchymal stromal cells into osteoblasts. [electronic resource]
- BMC cancer Jun 2010
- 298 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
ISSN: 1471-2407
Standard No.: 10.1186/1471-2407-10-298 doi
Subjects--Topical Terms: Adolescent Adult Alkaline Phosphatase--metabolism Ascorbic Acid--pharmacology Bone Marrow Cells--drug effects Calcification, Physiologic--drug effects Cell Differentiation--drug effects Cell Proliferation--drug effects Cell Separation Cells, Cultured Child Child, Preschool Dasatinib Dexamethasone--pharmacology Dose-Response Relationship, Drug Extracellular Matrix--drug effects Gene Expression Regulation--drug effects Glycerophosphates--pharmacology Humans Integrin-Binding Sialoprotein Kinetics Mesenchymal Stem Cells--drug effects Middle Aged Osteoblasts--drug effects Osteogenesis--drug effects Osteopontin--metabolism Phosphorylation Protein Kinase Inhibitors--pharmacology Proto-Oncogene Mas Pyrimidines--pharmacology RANK Ligand--metabolism Sialoglycoproteins--metabolism Thiazoles--pharmacology Young Adult src-Family Kinases--antagonists & inhibitors